DJIA 18,264.92 -20.82 -0.11%
NASDAQ 5,101.92 11.13 0.22%
S&P 500 2,130.72 -0.10 0.00%
market minute promo

169.35 0.78 (0.46%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

ALXN $169.35 0.46%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $167.69
Previous Close $168.57
Daily Range $167.31 - $171.35
52-Week Range $150.06 - $203.30
Market Cap $33.8B
P/E Ratio 57.73
Dividend (Yield) $0.00 (0.0%)
Volume 613,448
Average Daily Volume 2,220,740
Current FY EPS $4.82




Drug Makers

Alexion Pharmaceuticals, Inc. (ALXN) Description

A biotechnology company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. Website:

News & Commentary Rss Feed

Why I'm Buying Sarepta Therapeutics Stock

Sarepta Therapeutics got some great news from the FDA yesterday that sent shares soaring. Here's why the stock is definitely worth a deeper dive by risk-tolerant investors.

Why I Bought The Dips In Both Gilead And Achillion Today

Consolidation Is Good - Cramer's Mad Money (5/18/15)

Biotech Stock Roundup: Alexion to Buy Synageva, FDA Panel Backs Vertex's Orkambi - Analyst Blog

Short Sellers Start to Get Nervous on Biotech

ETFs in Focus on Impressive Q1 Biotech Earnings - ETF News And Commentary

ETFs in Focus on Impressive Q1 Biotech Earnings - ETF News And Commentary

Oppenheimer Downgrades Dyax

Yellen Sounds A Warning, Nasdaq Falls But Biotech Hangs On

Investors Just Doubled Their Money on This Stock

Alexion is paying $8.4 billion to buy Synageva, a company without any sales, so in today's episode we're digging into this deal to see what it may mean to biotech investors.

Will Suitors Line Up to Buy These Biotech Stocks Next?

BioMarin Therapeutic Inc. and Amicus Therapeutics, Inc. are working on ultra-rare disease drugs that could attract an acquirer.

See More ALXN News...

ALXN's Top Competitors

ALXN $169.35 (0.46%)
Current stock: ALXN
AMGN $163.50 (-0.21%)
Current stock: AMGN
GILD $112.12 (0.81%)
Current stock: GILD
BIIB $399.59 (-0.39%)
Current stock: BIIB